DUBLIN, Oct. 05 2015 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/2mzgt5/global) has announced the addition of the "Global Radiofrequency Ablation Devices Market Assessment & Forecast: 2015-2019" report to their offering.
The global RF ablation devices market is greatly influenced by the segment or application of devices. There are several players operating in multiple segments such as renal denervation, arthroscopy and pain management together. Acquisitions and mergers have further increased competition of companies and the market shows a trend of consolidation of core competencies in radiofrequency ablation technologies.
RFA has become the image-guided minimally invasive technique of choice today due to its efficacy, safety, and ease of use. This procedure is also often reserved for patients with comorbidities and those who are inoperable for other reasons and one of the major driving factors for this technology is the fact that a large number of cases are treated as out-patient procedures reducing hospital stay and expenditure. Tumor management and cardiac rhythm management were the largest applications accounting for 60.3% of the market for RF devices across the world. In 2014, revenue generated from devices sold for tumor management across the world accounted for a share of 36.1%. Overall clinical applications of RF energy involve 3 major actions on the body; ablation of cancerous tissue, ablation of obstructive and excessive tissue, denervation or deadening of nerves.
Approximately 750,000 new cases of liver cancer are diagnosed each year annually with more than 20,000 being in United States and around 5,000 in the United Kingdom. RF ablation presents one of the best treatment options for solid tumor in liver due to a lack of other alternatives. Lung cancer occurs in over 2.5 million people across the globe and is the leading cause of cancer death with an estimated 1.6 million deaths annually. Although a large percentage of patients are not eligible for surgery, a growing fraction of population is suitable for minimally invasive RF ablation procedure.
Stryker offers RF ablation portfolio for both pain management and arthroscopy, similarly Medtronic Inc (and Covidien) together offer a large RF device portfolio targeting general surgery, renal denervation and tumor management. Major players in this market are Medtronic Inc, Johnson & Johnson, Boston Scientific, St. Jude Medical, Stryker, Arthrex, Haylard Health, Angiodynamics, AtriCure, Sutter and Smith & Nephew. Overall the market is quite fragmented and the industry continues to see consolidation in major therapeutic areas such as cardiac ablation and general surgery.
Key Topics Covered:
Chapter 1 Preface
Chapter 2 Précis
Chapter 3 Market Dynamics
Chapter 4 Radiofrequency Ablation Devices - Global Market Size Assessment, by Applications, Forecast: 2015 - 2019
Chapter 5 Radiofrequency Ablation Devices - Global Market Size Assessment, by Products, Forecast: 2015 - 2019
Chapter 6 Radiofrequency Ablation Devices - Global Market Size Assessment, by Geography, Forecast: 2015 - 2019
Chapter 7 Key Players Analysis: Radiofrequency Ablation Devices Market Share, 2014 (%)
Chapter 8 Epilogue
Companies Mentioned
- AngioDynamics
- Arthrex
- AtriCure Inc.
- Biotronik
- Boston Scientific Corporation
- Cosman Medical Inc.
- Diros Technology
- Fcare Systems
- Haylard Health Inc.
- Hologic (Novasure)
- Johnson & Johnson (Biosense Webster & DePuy Mitek)
- Medtronic Inc (Covidien PLC)
- St. Jude Medical
- Stockert
- Stryker
- Stryker Corporation
- Sutter Medizintechnik GmbHTopera (Abbott Laboratories)
For more information visit http://www.researchandmarkets.com/research/2mzgt5/global
Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net
